DMRA · Damora Therapeutics, Inc.
$30.33
-0.49 (-1.59%)
At close · Aug 24
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.90B
Shares
61.74M
Weekly off-exchange (dark pool / OTC) trading volume reported to FINRA under its OTC/ATS Transparency data. ATS volume is executed on alternating trading systems (dark pools); non-ATS OTC is other over-the-counter dealer volume. The off-exchange share is total off-exchange volume as a percentage of consolidated weekly trading volume for the same Monday–Friday week.
Off-Exchange Volume History
| Week Start | ATS Volume | Non-ATS OTC Volume | Total Off-Exchange | % of FINRA Weekly Volume |
|---|---|---|---|---|
| 2026-07-20 | 1,058,752 | 149,061 | 1,207,813 | 49.7% |
| 2026-07-13 | 889,888 | 110,297 | 1,000,185 | 44.1% |
| 2026-07-06 | 1,175,246 | 375,580 | 1,550,826 | 49.2% |
| 2026-06-29 | 965,454 | 122,010 | 1,087,464 | 44.7% |
| 2026-06-22 | 896,160 | 2,272,285 | 3,168,445 | 30.8% |
| 2026-06-15 | 634,833 | 682,002 | 1,316,835 | 43.4% |
| 2026-06-08 | 624,344 | 196,401 | 820,745 | 45.2% |
| 2026-06-01 | 860,686 | 96,715 | 957,401 | 50.5% |
| 2026-05-25 | 362,859 | 268,905 | 631,764 | 36.8% |
| 2026-05-18 | 411,870 | 243,618 | 655,488 | 47.7% |
| 2026-05-11 | 582,643 | 264,226 | 846,869 | 46.9% |
| 2026-05-04 | 322,951 | 1,591,218 | 1,914,169 | 73.1% |
| 2026-04-27 | 237,821 | 158,100 | 395,921 | 42.6% |
| 2026-04-20 | 222,280 | 85,276 | 307,556 | 36.8% |
| 2026-04-13 | 469,667 | 377,928 | 847,595 | 49.0% |
| 2026-04-06 | 359,392 | 102,667 | 462,059 | 40.4% |
| 2026-03-30 | 164,089 | 69,297 | 233,386 | 26.2% |
| 2026-03-23 | 442,702 | 126,779 | 569,481 | 44.8% |
| 2026-03-16 | 879,307 | 155,839 | 1,035,146 | 44.4% |
Showing 1–19 of 19 weeks
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
102 filings
101 filers
Visit website
Investor relations